NABL Accredited · IP & JP Compliant · HPLC Analysis

Voglibose Analysis as per IP and JP

Advanced HPLC analysis of Voglibose using post-column fluorescence derivatization. Compliant with Indian Pharmacopoeia 2014 and Japanese Pharmacopoeia standards.

What is Voglibose?

Voglibose is an alpha-glucosidase inhibitor developed in 1994 by Takeda Pharmaceuticals Industries Ltd. It is effectively used for diabetes treatment by delaying glucose absorption at the intestinal level and preventing a sudden surge of glucose after meals. Voglibose shows high activity, allowing small doses to be effective while minimizing side effects in the gastrointestinal tract.

Why Specialized Analysis is Required

The absence of a chromophore or conjugation in the Voglibose molecule makes it difficult to detect by standard spectroscopic absorption in the UV-Visible region. Conventional analytical methods fail to provide the sensitivity and selectivity required for pharmaceutical analysis. To overcome this limitation, post-column derivatization with a fluorescence agent provides high sensitivity and selectivity for accurate quantification and identity confirmation.

Our Testing Methodology

Auriga Research employs an advanced HPLC system with post-column fluorescence derivatization, following the methodology notified in Japanese Pharmacopoeia (16th edition) and Indian Pharmacopoeia (2014). Our test conditions provide high precision and sensitivity:

Column: SS amino column 250mm × 4.6mm × 5μm
Column Temperature: 25°C
Mobile Phase: 37:63 mixture of phosphate buffer (pH 6.5) and acetonitrile
Flow Rate: 0.6 ml/min
Reaction Coil Temperature: 100°C
Detector: Fluorescence with excitation at 350nm and emission at 430nm
Derivatization Agent: Taurine (6.25g) + Sodium periodate (2.56g) in 1000ml water

This post-column fluorescence derivatization system overcomes the detection limitations of the Voglibose molecule and delivers regulatory-grade analytical results with high precision and selectivity.

Regulatory Compliance

Our analytical methodology is fully compliant with:

Indian Pharmacopoeia 2014 — Voglibose monograph
Japanese Pharmacopoeia 16th edition — Voglibose assay method
CDSCO regulatory requirements for pharmaceutical testing
International quality standards for active pharmaceutical ingredients

Applications

Our Voglibose analysis service supports a wide range of pharmaceutical applications:

Raw material identification and purity assessment
Finished pharmaceutical formulation assay (tablets, capsules, oral solutions)
Method development and validation projects
Stability studies and shelf-life prediction
Regulatory dossier support for CDSCO, US FDA, and EMA submissions
Post-approval change (SUPAC) analysis for manufacturing site or formulation changes

Who Should Use This Service

Pharmaceutical manufacturers producing Voglibose-containing products
Contract manufacturers requiring specialized HPLC analysis
API suppliers seeking IP/JP-compliant quality control testing
Generic drug developers preparing regulatory submissions
Quality assurance teams requiring post-column derivatization expertise
CROs and development organizations needing specialized analytical capability

Once you fill out the form, you will:

Receive a call or email from our team to understand your exact Voglibose testing requirement
Get a detailed proposal including methodology, turnaround time, and pricing
Receive guidance on sample preparation and submission
Obtain regulatory-grade analytical reports with full documentation and traceability

Frequently Asked Questions

What is Voglibose and how does it work?

Voglibose is an alpha-glucosidase inhibitor developed in 1994 by Takeda Pharmaceuticals Industries Ltd. It is used for diabetes treatment by delaying glucose absorption at the intestinal level, which prevents a sudden surge of glucose after meals. It shows high activity, allowing small doses to be effective while minimizing gastrointestinal side effects.

Why is Voglibose analysis challenging?

Voglibose lacks a chromophore or conjugation in its molecular structure, making it difficult to detect using standard spectroscopic absorption in the UV-Visible region. This requires specialized analytical methods such as post-column derivatization with fluorescence agents to achieve high sensitivity and selectivity.

What standards does Auriga Research follow for Voglibose analysis?

Our laboratory follows the post-column fluorescence derivatization method notified in the Japanese Pharmacopoeia (16th edition) and Indian Pharmacopoeia (2014). These are internationally recognized standards that ensure accuracy, precision, and regulatory compliance.

What is the testing methodology used by Auriga Research?

We employ an HPLC system with post-column fluorescence derivatization. The method uses an SS amino column (250mm x 4.6mm x 5μm), phosphate buffer/acetonitrile mobile phase, fluorescence detection at excitation 350nm and emission 430nm, and Taurine-based derivatization agent for high sensitivity and selectivity.

Can Auriga Research test raw materials and pharmaceutical formulations?

Yes. We provide comprehensive Voglibose analysis for both raw materials and finished pharmaceutical formulations. Our methodology delivers high precision and sensitivity for accurate quantification and identity confirmation across all product types.

What are the advantages of post-column fluorescence derivatization?

Post-column fluorescence derivatization provides high precision and sensitivity for detecting Voglibose in pharmaceutical formulations. The method overcomes the detection limitations of UV-Visible spectroscopy and delivers reproducible, regulatory-grade results compliant with IP and JP standards.